These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20179707)

  • 1. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
    Porta C
    Br J Cancer; 2010 Mar; 102(7):1196-7. PubMed ID: 20179707
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
    Charbonneau C; Sandin R
    Br J Cancer; 2010 Oct; 103(8):1307-8; author reply 1309-10. PubMed ID: 20938457
    [No Abstract]   [Full Text] [Related]  

  • 3. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
    Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
    Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
    Ravasio R; Ortega C; Sabbatini R; Porta C
    Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
    Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
    Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
    Schmidinger M; Zielinski CC
    Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
    Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
    J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
    BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
    Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L
    BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
    Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
    Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on systemic therapies of metastatic renal cell carcinoma.
    Herrmann E; Bierer S; Wülfing C
    World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
    Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
    J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.
    Bradshaw MJ; Cheville JC; Croghan GA
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):61-4. PubMed ID: 21326149
    [No Abstract]   [Full Text] [Related]  

  • 20. [First-line therapy of metastatic renal cell carcinoma--update 2009].
    Miller K
    Onkologie; 2010; 33 Suppl 1():5-9. PubMed ID: 20164669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.